Navigation Links
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
Date:11/25/2008

SUNNYVALE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the company has completed a Phase 1 clinical trial with PCI-27483, the company's novel, first-in-class small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16) healthy volunteers to evaluate the safety and pharmacologic effect of PCI-27483. A single administration of PCI-27483 resulted in a linear dose response in the International Normalized Ratio (INR), a routine laboratory test used to assess the level of anticoagulation (blood-thinning).

"Single doses of PCI-27483 reliably and quickly achieved therapeutic levels of anticoagulation without adverse effects in this initial trial," said James Lowder, M.D., Vice President, Clinical Development for Pharmacyclics. "The ability to achieve precise levels of anticoagulation that can be readily measured differentiates PCI-27483 from other available anticoagulants. The Factor VIIa: tissue factor complex, the pharmacologic target of PCI-27483, has been implicated both in the progression of solid tumors and the increased incidence of venous thromboembolic events observed in many malignancies. Up-regulation of tissue factor expression is observed in pancreatic, lung, and breast cancer, and is associated with a worsened prognosis."

In the recently completed study, PCI-27483 increased the INR with minimal intra-subject variation and a half-life of ten hours. At the highest subcutaneous dose of PCI-27483 evaluated, a mean (+/-standard error) peak INR of 2.72 (+/- 0.24) was achieved one to two hours post-dosing. The trial further established doses of PCI-27483, which upon repeated dosing are expected to maintain the INR in the range of 2.0 to 3.0, the target window for treatment and prevention of thromboembolic events (i.e., formation of blood clots).


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets has announced the addition of the ... Disorder) Market - Forecast to 2023" report to their ... human microbiome market is segmented by application, disease, product, and ... be valued as $294 million in 2019 and is poised ... period of 2019-2023. The market is driven by growing incidences ...
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... WALTHAM, Mass. , Sept. 19, 2014  Alere ... in rapid diagnostics, issued the following statement today in ... Combating Antibiotic-Resistant Bacteria. "As the global leader ... President for establishing a national strategy to address the ... continuing to work with the Administration on initiatives to ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
(Date:9/19/2014)... kids transition from elementary to middle school, they are ... study. But the researchers studying U.S schoolkids ... physical bullying declines as students get older. Because ... address all types of bullying as well as differences ... The study was published recently in School Psychology ...
(Date:9/19/2014)... 19, 2014 Hastings and Hastings, a discount ... the industry, announces a record number of visitors to its ... variety of serious injury cases as well as auto accident ... bite related accident cases and others. Having served the state ... stood the test of time when it comes to dedicated ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... -- Your brain structure could help predict how willing you ... Researchers at Yale University found those with greater volume in ... may be more likely to engage in risky behavior than ... study, funded by the U.S. National Institute on Aging, involved ... the Northeast. The researchers sought to determine how brain structure ...
(Date:9/19/2014)... 2014 (HealthDay News) -- The U.S. Food and Drug Administration ... Trulicity is part of a class of once-a-week injectable drugs ... 2 diabetes. "Trulicity is a new treatment option, ... regimens to control blood sugar levels in the overall management ... the FDA,s Office of Drug Evaluation II, said in an ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... child filed a motion in federal court today to confirm settlement ... The family alleged in the suit that the insurer wrongfully ... (ASD), on the baseless ground that the care was "experimental." ... at a court-ordered conference on Wednesday, June 17, 2009, Blue Cross ...
... between gray matter and dopamine levels in patients , ... levels of the neurotransmitter dopamine may explain brain gray ... study suggests. , Previous research found an association between ... wasn,t known, the researchers wrote. , In this new ...
... treatment delays and jeopardize care, review suggests, , FRIDAY, June ... lecturer at the University of Toronto, was enjoying a rare ... beeped. , "I answered the page, and there was the ... been calling repeatedly to try to get in touch with ...
... , Brio Active opens its doors this month, offering a ... its core. , , DENVER, June 19 Brio ... vibration, a relatively new fitness concept in the U.S., with ... strength, flexibility, balance, energy, bone density, and neuromuscular coordination. ...
... 19 Bertalan Mesko, medical blogger and health 2.0 consultant, ... by Federico Semeraro, MD and the D-Sign Team, that provides ... but not everyone is trained to be able to perform ... to do it through clear instructions and images. , ...
... WHITE PLAINS, N.Y., June 19 Kenneth A. May, former CEO ... Trustees of the March of Dimes, it was announced today. , ... for our mission, especially our Prematurity Campaign," said Dr. Jennifer L. ... Ken,s continued leadership as we work towards our goal of giving ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 2Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 3Health News:Pages to Doctors Don't Always Hit the Mark 2Health News:Pages to Doctors Don't Always Hit the Mark 3Health News:Brio Active Brings Whole Body Vibration Fitness to Cherry Hills Village 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Medicine Products: